Skip to main content
Clinical Trials/JPRN-jRCTs031220653
JPRN-jRCTs031220653
Recruiting
Phase 3

Efficacy of Nutritional Support and Prehabilitation in Patients who have Resectable Pancreatic Ductal Adenocarcinoma and Undergo Preoperative Chemotherapy: Non-Blinded Randomized Controlled Trial

Hasegawa Kiyoshi0 sites60 target enrollmentFebruary 22, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Pancreatic cancer
Sponsor
Hasegawa Kiyoshi
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 22, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hasegawa Kiyoshi

Eligibility Criteria

Inclusion Criteria

  • 1\. With resectable pancreatic cancer scheduled for neoadjuvant chemotherapy, gemcitabine and S\-1, and pancreatic resection
  • 2\. ASA performance status of 1\-2
  • 3\. Aged between 18 and 85 years old at the time of informed consent is taken
  • 4\. Male or female
  • 5\. Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
  • 6\. Able to attend all scheduled visits

Exclusion Criteria

  • 1\. Having history of hypersensitivity to component of ENORAS Liquid
  • 2\. With milk protein allergy
  • 3\. With ileus
  • 4\. With loss of bowel function
  • 5\. With severe liver diseases, renal diseases or cardiac diseases, judged based on grade 3 of CTCAE v5\.0\- JCOG
  • 6\. Having hemodialysis
  • 7\. With disorder of glucose metabolism such as severe diabetes mellitus
  • 8\. With congenital disorder of amino acid metabolism
  • 9\. Women of childbearing potential, pregnant women or breast\-feeding women
  • 10\. Disable to having prehabilitation due to impaired cardiopulmonary function

Outcomes

Primary Outcomes

Not specified

Similar Trials